1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial

We sought to assess the safety and efficacy of the novel VESTAsync-eluting stent (MIV Therapeutics, Atlanta, Georgia) combining a stainless steel platform with a nanothin-microporous hydroxyapatite surface coating impregnated with a polymer-free low-dose of sirolimus (55 microg). Durable polymers in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JACC. Cardiovascular interventions 2009-05, Vol.2 (5), p.422-427
Hauptverfasser:	Costa, Jr, J Ribamar, Abizaid, Alexandre, Costa, Ricardo, Feres, Fausto, Tanajura, Luiz Fernando, Abizaid, Andréa, Maldonado, Galo, Staico, Rodolfo, Siqueira, Dimytri, Sousa, Amanda G M R, Bonan, Raoul, Sousa, J Eduardo
Format:	Artikel
Sprache:	eng
Schlagworte:	Angioplasty, Balloon, Coronary Aspirin Coronary Angiography Coronary Artery Bypass Coronary Artery Disease - diagnostic imaging Coronary Artery Disease - drug therapy Coronary Artery Disease - therapy Coronary Restenosis Drug-Eluting Stents Durapatite Female Humans Intensive Care Units Male Middle Aged Platelet Aggregation Inhibitors - therapeutic use Polymers Prospective Studies Sirolimus - administration & dosage Sirolimus - therapeutic use Ticlopidine - analogs & derivatives Ticlopidine - therapeutic use Time Factors Ultrasonography
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!